Incannex Healthcare Limited (IXHL)
USD 0.58
(-1.71%)
USD 0.58
(-1.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -30.04 Million USD | 39.52% |
| 2023 | -17.71 Million AUD | -56.03% |
| 2022 | -11.35 Million AUD | -32.39% |
| 2021 | -8.57 Million AUD | -197.11% |
| 2020 | -2.88 Million AUD | -3.63% |
| 2019 | -2.78 Million AUD | 12.94% |
| 2018 | -3.19 Million AUD | 85.08% |
| 2017 | -21.43 Million AUD | -2673.33% |
| 2016 | -772.94 Thousand AUD | 68.88% |
| 2015 | -2.48 Million AUD | 62.72% |
| 2014 | -6.66 Million AUD | 48.41% |
| 2013 | -12.91 Million AUD | -302.07% |
| 2012 | -3.21 Million AUD | 29.13% |
| 2011 | -4.53 Million AUD | -270.85% |
| 2010 | 2.65 Million AUD | 194.99% |
| 2009 | -2.79 Million AUD | -156.54% |
| 2008 | -1.08 Million AUD | -3.46% |
| 2007 | -1.05 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -9.74 Million USD | -22.06% |
| 2024 Q3 | -7.41 Million USD | 7.12% |
| 2024 Q2 | -7.98 Million USD | -90.34% |
| 2024 Q1 | -7.5 Million USD | 5.02% |
| 2023 Q3 | -3.65 Million USD | -0.33% |
| 2023 Q2 | -3.63 Million USD | 90.81% |
| 2023 Q1 | -39.59 Million USD | -470.06% |
| 2023 Q4 | -7.89 Million USD | -116.35% |
| 2023 FY | -17.71 Million AUD | -56.03% |
| 2022 FY | -11.35 Million AUD | -32.39% |
| 2022 Q4 | -6.94 Million USD | 0.0% |
| 2021 FY | -8.57 Million AUD | -197.11% |
| 2020 FY | -2.88 Million AUD | -3.63% |
| 2019 FY | -2.78 Million AUD | 12.94% |
| 2018 FY | -3.19 Million AUD | 85.08% |
| 2017 FY | -21.43 Million AUD | -2673.33% |
| 2016 FY | -772.94 Thousand AUD | 68.88% |
| 2016 Q3 | -193.23 Thousand AUD | 69.37% |
| 2016 Q4 | -193.23 Thousand AUD | 0.0% |
| 2016 Q1 | -630.94 Thousand AUD | 0.0% |
| 2016 Q2 | -630.94 Thousand AUD | 0.0% |
| 2015 Q1 | -3.3 Million AUD | 0.0% |
| 2015 FY | -2.48 Million AUD | 62.72% |
| 2015 Q4 | -630.94 Thousand AUD | 0.0% |
| 2015 Q3 | -630.94 Thousand AUD | 80.91% |
| 2015 Q2 | -3.3 Million AUD | 0.0% |
| 2014 Q2 | -3.22 Million AUD | 0.0% |
| 2014 FY | -6.66 Million AUD | 48.41% |
| 2014 Q3 | -3.3 Million AUD | -2.38% |
| 2014 Q4 | -3.3 Million AUD | 0.0% |
| 2014 Q1 | -3.22 Million AUD | 0.0% |
| 2013 Q4 | -3.22 Million AUD | 0.0% |
| 2013 Q1 | -803.04 Thousand AUD | 0.0% |
| 2013 Q2 | -803.04 Thousand AUD | 0.0% |
| 2013 FY | -12.91 Million AUD | -302.07% |
| 2013 Q3 | -3.22 Million AUD | -302.07% |
| 2012 FY | -3.21 Million AUD | 29.13% |
| 2012 Q4 | -803.04 Thousand AUD | 0.0% |
| 2012 Q3 | -803.04 Thousand AUD | 29.13% |
| 2012 Q2 | -1.13 Million AUD | 0.0% |
| 2012 Q1 | -1.13 Million AUD | 0.0% |
| 2011 Q4 | -1.13 Million AUD | 0.0% |
| 2011 FY | -4.53 Million AUD | -270.85% |
| 2011 Q3 | -1.13 Million AUD | -270.85% |
| 2011 Q1 | 663.26 Thousand AUD | 0.0% |
| 2011 Q2 | 663.26 Thousand AUD | 0.0% |
| 2010 Q3 | 663.26 Thousand AUD | 168.91% |
| 2010 Q4 | 663.26 Thousand AUD | 0.0% |
| 2010 FY | 2.65 Million AUD | 194.99% |
| 2010 Q1 | -962.53 Thousand AUD | 0.0% |
| 2010 Q2 | -962.53 Thousand AUD | 0.0% |
| 2009 Q1 | -272.17 Thousand AUD | 0.0% |
| 2009 Q4 | -962.53 Thousand AUD | 0.0% |
| 2009 Q2 | -272.17 Thousand AUD | 0.0% |
| 2009 Q3 | -962.53 Thousand AUD | -253.64% |
| 2009 FY | -2.79 Million AUD | -156.54% |
| 2008 Q3 | -272.17 Thousand AUD | -3.13% |
| 2008 Q1 | -263.92 Thousand AUD | 0.0% |
| 2008 FY | -1.08 Million AUD | -3.46% |
| 2008 Q4 | -272.17 Thousand AUD | 0.0% |
| 2008 Q2 | -263.92 Thousand AUD | 0.0% |
| 2007 Q3 | -263.92 Thousand AUD | 0.0% |
| 2007 FY | -1.05 Million AUD | 0.0% |
| 2007 Q4 | -263.92 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alvotech | -354.86 Million USD | 91.534% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 117.993% |
| Journey Medical Corporation | -2.07 Million USD | -1349.156% |
| Dynavax Technologies Corporation | -37.02 Million USD | 18.87% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 81.151% |
| PainReform Ltd. | -9.58 Million USD | -213.449% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -527.777% |
| SCYNEXIS, Inc. | 72.66 Million USD | 141.339% |
| Silver Spike Investment Corp. | 7.34 Million USD | 509.272% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -527.777% |
| Bright Green Corporation | -8.89 Million USD | -237.867% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 80.689% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -98.921% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 163.956% |
| Alpha Teknova, Inc. | -35.56 Million USD | 15.527% |
| Embecta Corp. | 221.5 Million USD | 113.563% |
| Safety Shot Inc | -12.18 Million USD | -146.558% |
| Procaps Group, S.A. | 38.97 Million USD | 177.082% |
| Cosmos Health Inc. | -21.83 Million USD | -37.606% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -1094.37% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 134.264% |
| Theratechnologies Inc. | -10.62 Million USD | -182.686% |
| Harrow Health, Inc. | 580 Thousand USD | 5279.483% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -539.034% |
| Biofrontera Inc. | -22.67 Million USD | -32.473% |
| DURECT Corporation | -36.88 Million USD | 18.553% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -470.146% |
| Cronos Group Inc. | -81.37 Million USD | 63.083% |
| OptiNose, Inc. | -22.74 Million USD | -32.06% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 114.371% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 23.273% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 337.817% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 339.848% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -592.777% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -383.688% |
| Radius Health, Inc. | -3.92 Million USD | -665.376% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -751.798% |
| ProPhase Labs, Inc. | -21.61 Million USD | -38.995% |
| Phibro Animal Health Corporation | 53.31 Million USD | 156.346% |
| Procaps Group S.A. | 52.32 Million USD | 157.413% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -252.47% |
| Viatris Inc. | 766.2 Million USD | 103.921% |
| Rockwell Medical, Inc. | -6.67 Million USD | -350.39% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -471.774% |
| SIGA Technologies, Inc. | 83.62 Million USD | 135.925% |
| Tilray Brands, Inc. | -174.74 Million USD | 82.809% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 421.948% |
| Shineco, Inc. | -17.06 Million USD | -76.03% |
| PetIQ, Inc. | 60.01 Million USD | 150.056% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -534.214% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 111.973% |
| Alimera Sciences, Inc. | -1.47 Million USD | -1942.216% |
| Assertio Holdings, Inc. | -243.53 Million USD | 87.665% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -409.828% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -120.608% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | -92.645% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -49.83% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 78.207% |
| Hempacco Co., Inc. | -8.81 Million USD | -240.899% |
| Talphera, Inc. | -16.88 Million USD | -77.873% |
| Alvotech | -354.86 Million USD | 91.534% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 156.2% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 108.238% |
| Currenc Group, Inc. | -6.64 Million USD | -352.031% |
| Kamada Ltd. | 10.06 Million USD | 398.5% |
| Indivior PLC | -4 Million USD | -651.025% |
| Evoke Pharma, Inc. | -7.43 Million USD | -304.272% |
| Flora Growth Corp. | -50.35 Million USD | 40.34% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -49.83% |
| Evolus, Inc. | -49.23 Million USD | 38.982% |
| HUTCHMED (China) Limited | 18.37 Million USD | 263.488% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 115.25% |
| Akanda Corp. | -10.05 Million USD | -198.875% |